RNAi vitamin D conjugates
AssigneeExtend Biosciences, Inc.
InventorsTarik Soliman, Laura M. Hales, Daniel B. Hall, Howard P. Sard, Vishnumurthy Hegde
Life of this patent
Estimating the term…
Abstract
The invention provides non-hormonal vitamin D conjugated to therapeutic RNA compounds that result in the compounds having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the therapeutic RNA compounds via the third carbon on the vitamin D backbone.
Claims14
A carrier-drug conjugate comprising a targeting group that is a non-hormonal vitamin D conjugated to a therapeutic RNA compound at the carbon 3 position of said non-hormonal vitamin D targeting group.
A pharmaceutical composition comprising a carrier-drug conjugate comprising a targeting group that is a non-hormonal vitamin D conjugated via a scaffold at the carbon 3 position to a therapeutic RNA compound having a nucleic acid sequence with at least a 90% sequence identity to SEQ ID NO:1.
A carrier-drug conjugate comprising a targeting group that is vitamin D non-releasably conjugated to a therapeutic RNA compound, wherein said therapeutic RNA compound is conjugated at the carbon 3 position of said non-hormonal vitamin D targeting group.
Dependencies are inferred from the claim text.